UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): **February 9, 2015**

PLASMATECH BIOPHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware	**0-9314**	**83-0221517**
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

4848 Lemmon Avenue, Suite 517, Dallas, TX 75219
(Address of principal executive offices) (Zip Code)

(214) 905-5100
(Registrant's telephone number, including area code)

PLASMATECH BIOPHARMACEUTICALS, INC.
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure
Item 8.01. Other Items

Presentations relating to our technology, business and corporate financial structure will be made to investors during February and March 2015. The presentation is attached as Exhibit 99.1 and is incorporated herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Presentation entitled “PlasmaTech Biopharmaceuticals”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PlasmaTech Biopharmaceuticals, Inc.
(Registrant)

By: /s/ Stephen B. Thompson
Stephen B. Thompson
Vice President Finance
Chief Accounting Officer

Date: February 9, 2015

EXHIBIT INDEX

Exhibit Number	
99.1	Presentation entitled “PlasmaTech Biopharmaceuticals”

PLASMATECH BIOPHARMACEUTICALS

Company Overview

Q1 2015

Safe Harbor Statement

This presentation contains certain statements that may be forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including statements relating to the product portfolio and pipeline and clinical programs of the company, the market opportunities for the Plasma Technologies fractionation technology, MuGard, ProctiGard, and the other mucoadhesive hydrogel products, and the company's goals and objectives. These statements are subject to numerous risks and uncertainties, including but not limited to the risks detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, and other reports filed by the company with the Securities and Exchange Commission.

This presentation does not constitute an offer or invitation for the sale or purchase of securities or to engage in any other transaction with PlasmaTech or its affiliates. The information in this presentation is not targeted at the residents of any particular country or jurisdiction and is not intended for distribution to, or use by, any person in any jurisdiction or country where such distribution or use would be contrary to local laws or regulations.

Investment Highlights

- ✓ ***Commercial stage biopharmaceutical company driving innovation in plasma proteins***
- ✓ ***Patented, disruptive fractionation process***
  - ~$21bn market, 11% CAGR
  - Alpha-1 Proteinase Inhibitor ("A1PI") shortage looming, poor Cohn yield
  - SDF Process increases yields and margins
  - A1PI, Immunoglobulin, Ultra-orphan protein targets
- ✓ ***Focus on A1PI***
- ✓ ***Polymer Hydrogel Technology***
- ✓ ***Business Development – Partnering / M&A***

Product Pipeline Targeting > $17B

PLASMATECH BIOPHARMACEUTICALS

Salt Diafiltration Process ("SDF Process")

	Complete	2014	2015	2016	2017	*2017 Market Opportunity*
SDF Alpha™ (Alpha-1)	Process validation, Patent	PTBI License, Manufacturer Qualification	Pre-IND, IND Filing	Clinical Study, BLA Filing	Commercial	**> $ 2.5B**
SDF Gamma™ (IVIG)			Process Validation	TBD	TBD	**~$ 11.5B**
SDF Other Proteins			Discovery	Discovery	TBD	**> $ 1B**
				Plasma Protein Addressable Markets		*~$15B*

PHT: Polymer Hydrogel Technology Platform

	Complete	2014	2015	2016	2017	*2015 Market Opportunity*
MuGard®	510(k) US: AMAG, China: RHEI		Europe: Norgine, Korea: Hanmi	Ongoing global commercial optimization		**> $1B**
ProctiGard™		510(k)	Commercial			**> $500M**
				Oncology Supportive Care Markets		*> $2B*

Significant Plasma Therapeutics Opportunity

PLASMATECH BIOPHARMACEUTICALS

✓ ***Large, Fast-Growing Market***

- WW market ~$21 billion, ~11% CAGR
- Growth driven by greater awareness of therapeutic potential plasma proteins, better and earlier diagnostics

✓ ***Supply Constraints Hampered by Cohn Process***

- Antiquated Cohn fractionation damages proteins
- Large fractionators slow to alter current process
- Plasma shortages looming & prices rising

✓ ***Considerable M&A, Strategic Activity***

- **Fractionation**: Grifols/Talecris $3.4Bn, Bain Capital/PRUK ~$280m, Baxter /Kamada Glassia™
- **Biologics** : Pfizer/Hospira $15B, Roche/Intermune $8.3B, Sanofi/Genzyme $20B, Teva/Sicor $3.4B



2015 WW Market by Protein	$, M	
IgG	44%	9,128
All Factors	19%	3,888
Albumin	11%	2,310
Hyper Immune	5%	1,035
A1PI	**6%**	**1,215**
Fibrin	8%	1,572
C-1	4%	733
Other	4%	921
	100%	20,803

Robert, Patrick (2014, September), MRB: Marketing Research Bureau. *Global Plasma Supply and Product Demand.* Presented at IPFA/BCA Global Symposium on the Future for Blood and Plasma Donations, Sacramento, CA.

Highly Optimized PlasmaTech *SDF*™ Process

Enhancing Yields Drives Significant Value Per Liter of Plasma

PlasmaTech SDF Process	✓ **Simple 2-Stage Sodium Citrate Precipitation + Diafiltration** ✓ No ethanol or pH changes vs. Cohn Fractionation
Benefits of PlasmaTech Process	✓ **Alpha-1 yield increase ~10X** ✓ IVIG yield increase ~ 20% ✓ Potential for multiple ultra-orphan proteins
Positive Margin Impact	✓ **Yield improvements could drive 80% product margins versus ~30% Cohn process margin**
Abbreviated Regulatory Pathway	✓ **Abbreviated approval pathway under Section 351(a)**
Proprietary Intellectual Property	✓ **Three issued US and WW patents,** ✓ Foreign counterparts pending; additional patent filings

"The Cohn ethanol process utilizes multiple pH changes away from neutral which generates untoward side reactions that can alter (denature) the desired bio molecules."
Gene Zurlo

PlasmaTech will be the *only* company focused on *"Alpha-1 First"*

PLASMATECH BIOPHARMACEUTICALS

- ✓ ***Alpha-1 Proteinase Inhibitor– Serving Large Underserved Medical Need***
  - 2-4% penetration
- ✓ ***Driving Growth in Alpha-1 Market in next 3 years***
  - Early detection; newborn screening in NY and MA
  - Clinician awareness
  - New indications on horizon
- ✓ ***Looming Alpha-1 Supply Shortage***
  - Large fractionators slow to alter current processes
  - Cohn fractionation does not selectively target Alpha-1 ; poor Alpha-1 yield

"There is dramatic, continued increase in demand for plasma derived products globally; between 2017 and 2020, demand will outplace supply"
Robert Sandhaus, M.D., Ph.D.

#1 Clinical Target: *Inherited* COPD

PLASMATECH BIOPHARMACEUTICALS

AATD is an under-diagnosed hereditary condition

- Alpha-1 Antitrypsin Deficiency ("AATD"): Genetic condition: insufficient AAT protein produced by liver
- Alpha-1 protects lungs from inflammation and damage caused by infection and inhaled irritants
- AATD may lead to liver disease



COPD Medication

Treating 97-98% of total COPD patients for Acquired COPD

- ✓ Spiriva
- ✓ Serevent
- ✓ Brovana



Alpha-1 Augmentation Therapy: currently limited to treatment of Alpha-1 deficient individuals (Inherited COPD) who comprise 1-3% of all COPD patients.

"Inherited COPD is more prevalent than Cystic Fibrosis" Charlie Strange, MD

Alpha-1 Market

PLASMATECH BIOPHARMACEUTICALS

GRIFOLS
PROLASTIN C alpha1-proteinase inhibitor (human)

- Prolastin, Prolastin C
- Launched: 1988
- First A1PI

CSL Behring
Biotherapies for Life™
Zemaira

- Zemaira
- Launched: 2003

Baxter

- Aralast, Aralast MP
- Launched: 2003

KAMADA
High Quality Pharmaceuticals

- Glassia
- Launched: 2010
- Exclusive partnership: Baxter

Alpha-1 Market

- $900m: 2014
  - CAGR: 20-35%
- Pricing, US:
  - '15: $400/g
  - '16: $430/g
  - Price CAGR: 7%
- Inherited COPD
  - > 300k patients worldwide
  - ~ 10k current
  - 2-4% penetration

Alpha-1 Revenue Dynamics

- $102K per patient / year
- 1k patients > $100m recurring
- ~22 years, > $2.2m /patient

Alpha-1: Looming Supply Shortage

"This is an underappreciated problem that will affect the entire Alpha-1 community.

There is no current solution with the current systems and approach.

These numbers are accurate and make a compelling case for PlasmaTech's approach"

Robert Sandhaus, MD PhD



		2014	2015	2016	2017	2018	2019	2020
Market	Alpha1 Market Size, $M	900	1,215	1,640	2,214	2,989	4,036	5,448
	# Patients WW	9,419	11,884	14,993	18,917	23,867	30,112	37,992
	$000 per patient/year	96	102	109	117	125	134	143
Alpha1 Supply	Liters sourced for A1, M L	22.8	23.5	24.3	25.0	25.8	26.7	27.5
	Treatment Δ: # excess (untreated)	5,919	3,945	1,342	(2,059)	(6,470)	(12,158)	(19,464)
	Missed Revenue Opp, $M				(241)	(810)	(1,629)	(2,791)

- *Alpha-1 CAGR: 35%, Other plasma protein CAGR: 11%*
- *Global plasma capacity assumed growth: 3.2%/year, 23.5 million liters ww in 2015, 70% of total capacity applicable for Alpha-1*
- *Dose calculation: 5g/week*

Shortage potentially compounded by 2 additional factors

1. **New Indications**
2. **>5g dosing**

SDF™: Restructuring margins in target proteins

2017 Prices — process example: 150 k liters

	Cost					Alpha-1			IVIG	
	Plasma $/L	Process $/L	Plasma $M	Process $M	COGS $M	A1, kg	A1 $M $462/g	Patients	IVIG, kg	IVIG $M $80/g
Large Cohn	145	160	21.8	24.0	45.8	26	12	101	600	48
PlasmaTech SDF™	170	175	25.5	26.3	51.8	270	125	1,038	728	58
Difference	25	15	3.8	2.3	6.0	244	113	938	128	10

	Alpha-1 + IgG			Alpha-1		
	Revenue	GP, $M	GM, %	Revenue	GP, $M	GM, %
Large Cohn	60	14	24%	12	(34)	-277%
PlasmaTech SDF™	183	131	72%	125	73	59%
Difference		123	48%		113	336%

- ✓ **SDF Process radically improves yield & margin vs. Cohn**
- ✓ **Illustrates why smaller companies cannot manufacture Alpha-1 profitably**

351(a) BLA pathway follows previous A1PI approval pathway

✓ *Abbreviated Regulatory Pathway*

- BLA approval pathway 351(a) – estimate $ 5 to 9 million
- 12 month scale-up & analytical method development
- Replacement therapy efficacy and safety studies (50 target patients to 135 patients theoretical limit)
- PlasmaTech will work with PlasmaTech SAB and Alpha-1 Foundation to expedite study process

✓ *Collaborative Development & Commercial Strategy*

- Initiated contract manufacturing relationships
- **Will release data in 1H15**
- Multiple product opportunities enhance partnering opportunities globally



GLASSIA [Alpha-1 Proteinase Inhibitor (Human), Intravenous] Labeling Text

Table 1: Number of Subjects/Infusions/Adverse Events Occurring during the First 12 Weeks of Treatment

	GLASSIA	Prolastin
No. of subjects treated	33	17
No. of infusions	393	190
No. of subjects with adverse events regardless of causality (%)	27 (82%)	16 (94%)
No. of subjects with related adverse events according to investigator causality assessment (%)	6 (18%)	6 (35%)
No. of subjects with related serious adverse events	0	0
No. of subjects experiencing an adverse event within 24 hours of infusion, regardless of causality (%)	19 (58%)	14 (82%)
No. of adverse events regardless of causality (mean rate of adverse events per infusion)	70 (0.18)	46 (0.24)
No. of adverse events, regardless of causality, occurring within 24 hours of infusion (% of all adverse events)	35 (50%)	30 (65%)
No. of infusions associated with adverse events occurring within 24 hours of infusion, regardless of causality (% of infusions)	32 (8%)	28 (15%)

Kamada Glassia package insert:
http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM217890.pdf

PLASMATECH BIOPHARMACEUTICALS

SDF-Gamma™ Process produces IVIG: a high value protein

✓ ***PlasmaTech IVIG – increases IVIG yield by ~20%***

- Intravenous immunoglobulin (IVIG) is the high value plasma protein with multiple uses in patients with decreased or abolished antibody production capabilities
- ~44% of the total ~21bn plasma protein market

✓ ***Multiple targets for IVIG***

Neurology	Hematology	Dermatology	Other
✓ Guillain Barre	✓ Immune thrombo-cytopenia	✓ Kawasaki Syndrome	✓ Primary antibody deficiencies
✓ Lambert Eaton Syndrome	✓ Post BMT	✓ Dermatomyositis	✓ Vasculitis
✓ Multifocal motor neuropathy	✓ Myeloma and CLL	✓ Toxic epidermal necrolysis	✓ Autoimmune uveitis
✓ Myasthenia gravis	✓ Immune neutropenia	✓ Atopic dermatitis	✓ Birdshot retinochoro-idopathy
✓ Stiff person syndrome	✓ Parovirus B19 associated aplasia	✓ Blistering diseases	✓ Mucous membrane pemphigoid

GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] 10%

Hizentra

privigen

gamunex-C

Ultra Orphan Protein Discovery Platform

✓ ***Multiple High Value Ultra-Orphan Protein Products***

- >200 additional proteins in human plasma with therapeutic potential
- Denaturing impact of ethanol in Cohn process could create multiple product opportunities for PlasmaTech

✓ ***Other Possible Plasma Products***

- C-1-esterase inhibitor
- Protein C
- Anti-thrombin III
- Alpha-2-Macroglobulin
- Transferrin
- Plasminogin
- Haptoglobin
- Plasma gelsolin



Scientific Advisory Board

Leaders in Alpha-1 and Mucositis

Eugene Zurlo, BS, MS Pharmacy, *Chairman*

- 56 years experience
- Founder/Chairman/ Inventor Plasma Technologies, LLC (Licensor)
- Baxter Hyland, Millipore, NY Blood Center, Alpine Biologics, Ayerst Laboratories
- Launched first commercial AHF concentrate: **Hemofil**

Charles Heldebrant, PhD

- CSO PSC Biotec
- Alpha Therapeutic Corporation: Development, regulatory clearance, production of A1PI (sold to Baxter, now Aralast)
- Extensive experience in biological & pharmaceutical product development, regulatory, quality, validation,
- Holds 14 patents, author/co-author of 31 scientific / technical papers, extracts

Allan Louderback, PhD

- Head of Biomechanical Research: Baxter Hyland
- Founder/President CRO served: Baxter, Dade, Amgen, Biogen, Nichols, Technion, NY Blood Center
- 39 publications, listed on 44 patents
- Co-inventor Plasma Technologies SDF Process

YEARS OF ACCOMPLISHMENT — Robert "Sandy" Sandhaus, MD, PhD, describes the accomplishments of Charlie Strange, MD, that led to Strange's receiving the "Grateful Patient Award."

Charlie Strange, MD

- Professor Pulmonary, Critical Care, Allergy, and Sleep Medicine, Medical University of SC, Charleston SC
- Director: Alpha-1 Foundation Research Registry
- Clinical trial design & rare diseases expert, >200 publications

Robert Sandhaus, MD, PhD

- Professor of Medicine: National Jewish Health, Denver CO
- Clinical Director: Alpha-1 Foundation
- Medical Director, Founder: AlphaNet
- Extensive pharma industry expert: pathogenesis of emphysema.
- Extensive plasma therapeutics industry experience

Stephen T. Sonis, DMD, DMSc

- Clinical Professor of Oral Medicine, Harvard, Senior Surgeon, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Founder, CSO Biomodels
- Expert in epithelial injury due to cancer therapy
- Author >200 original publications, 9 books, 5 patents

Hydrogel Products & Platform

PLASMATECH BIOPHARMACEUTICALS

Proprietary Mucoadhesive Hydrogel Delivery System

- ✓ **Unique aqueous pseudoplastic liquid**
- ✓ **Patented mucoadhesive hydrogel delivery system enables extended delivery of drugs to mucosal tissue**
- ✓ **Broad patent coverage and claims (six patents granted, multiple pending).**
- ✓ **Patent extension opportunity for generic active drugs; multiple regulatory pathway via ANDA, 505(b)(2), 510(k) or IND/NDA pathways**

MuGard™ Oral Mucoadhesive → ***Oral Mucositis***

ProctiGard™ → ***Radiation Proctitis***

MuGard
Oral Mucoadhesive Hydrogel

PLASMATECH BIOPHARMACEUTICALS

Published in CANCER – May 1, 2014

- ✓ ***Protocol*** – Multi-center, randomized, placebo controlled study in 120 head and neck cancer patients
- ✓ ***Positive*** – MuGard ***statistically significant*** :
  - Primary endpoint of reduction in mouth and throat soreness (p=0.034)
  - Reduction in OM disease severity by WHO score at end of radiation treatment (p=0.038)
- ✓ ***Secondary Endpoints*** – Clinically important trends:
  - 10.0 day decrease in opioid use; duration of opioid use <50%
  - 3.9kg reduction in weight loss
  - 9 day delay in onset of oral mucositis
  - Very well tolerated with no SAEs
- ✓ ***First trial to show clinical benefit in oral mucositis for tough-to-treat head and neck cancer patients.***

Cancer

American Cancer Society

Novartis / UCLA MuGard Trial

- ✓ Novartis' Afinitor (everolimus), approved in various breast, pancreatic, renal and brain cancers
- ✓ Approximately 70% of Afinitor patients experience severe (painful, ulcerative) stomatitis that presents like oral mucositis
- ✓ Initiated by UCLA breast cancer clinician who have had success with MuGard in Afinitor patients experiencing OM; trial supported by Novartis, PlasmaTech, and AMAG
- ✓ Afinitor's approval in breast cancer should drive revenues by an additional $1.5 billion (analyst estimates for 2018 exceed $3.5 billion); reducing mucositis side effect could be an important value driver

Mucoadhesive Oral Wound Rinse (MuGard) in Preventing and Treating Stomatitis in Patients with ER- or PR-Positive Breast Cancer Receiving Everolimus

Management & Board of Directors

PLASMATECH BIOPHARMACEUTICALS

Management

Scott Schorer - *CEO*
- 19 years leadership- healthcare biologics, devices, healthcare IT
- President, CEO: CentriMed, IST
- President: Systagenix Wound Management

Harrison Wehner - *President & CFO*
- 21 years healthcare & biotech IB, financial advisory, M&A
- Senior positions: Canaccord Genuity, CitiGroup, UBS

Stephen Thompson – *VP Finance, Treasurer, Sec*
- 26 years financing and accounting
- Prior CFO and Controller experience

David Nowotnik, Ph.D. - SVP R&D
- 41 years experience pharmaceutical R&D, quality systems, regulatory affairs
- Bristol-Myers Squibb, Amersham International, Guilford Pharmaceuticals

Board of Directors

Steven Rouhandeh, *Chairman*
- SCO Capital Partners
- Founder SCO Financial Group
- Deutsche Bank, Cravath

Mark Alvino
- Bradley Woods, Griffin Securities

Stephen Howell, M.D.
- UCSD, UCSD Cancer Center
- Miliken Foundation prize: cancer chemo

Jeffrey Davis
- Former CEO Access (PlasmaTech)
- PlasmaTech consultant
- Phillips Medical Systems, Deutsche Bank

Mark Ahn, Ph.D.
- Genentech, Galena Biopharma, Bristol-Myers Squibb, Amgen

Numerous Valuable Near-Term Milestones

Events & Milestones	Estimated Timing
Global roll-out of MuGard for oral mucositis - ongoing	✓
FDA 510(K) marketing approval: ***ProctiGard™***	✓
MuGard® Partnerships: Norgine (Europe), Hanmi (Korea)	✓
SDF License Executed, New Management Team	✓
Norgine/Hanmi ***MuGard®*** commercial launches	2015
SDF Alpha™ release of data	1H 2015
SDF Alpha™ validation, characterization → IND filing	2015
SDF Alpha™ clinical study and BLA filing	2016
SDF Alpha™ regulatory approval and revenue	2016-17
Follow-on plasma product targets: ultra-orphan proteins, and additional hydrogel platform products	2016-17+

Valuation Comparables

Relative Valuations of Drug Delivery Companies / Related Companies

Market Analysis

(figures in millions, except per share data)		Price (1)			Revenue			Ent. Value / Revenue		
Company	Ticker	@ 1/31/15	Equity Value	Enterprise Value (2)	LTM	2014	2015	LTM	2014	2015
GRIFOLS SA-ADR	GRFS	$34.46	$13,513	$13,524	$4,252	$4,041	$4,370	3.2 x	3.3 x	3.1 x
NEKTAR THERAPEUTICS	NKTR	$14.64	$1,880	$1,774	$212	$199	$261	8.4 x	8.9 x	6.8 x
CHINA BIOLOGIC PRODUCTS INC	CBPO	$68.14	$1,680	$1,785	$228	$242	$283	7.8 x	7.4 x	6.3 x
DEPOMED INC	DEPO	$18.27	$1,073	$740	$236	$198	$231	3.1 x	3.7 x	3.2 x
PROMETIC LIFE SCIENCES INC	PLI CN	$1.49	$818	$837	$16	$22	$38	51.6 x	38.7 x	21.9 x
BIODELIVERY SCIENCES INTL	BDSI	$13.10	$672	$600	$40	$41	$84	14.9 x	14.7 x	7.2 x
AMAG PHARMACEUTICALS INC	AMAG	$44.19	$976	$756	$93	$125	$392	8.1 x	6.0 x	1.9 x
FLAMEL TECHNOLOGIES-SP ADR	FLML	$14.40	$556	$634	$30	$39	$197	20.8 x	16.2 x	3.2 x
ROCKWELL MEDICAL INC	RMTI	$10.79	$513	$521	$54	$53	$77	9.7 x	9.8 x	6.7 x
ANTARES PHARMA INC	ATRS	$2.34	$308	$260	$23	$26	$62	11.39 x	9.9 x	4.2 x
KAMADA LTD	KMDA	$4.03	$145	$101	$71	$70	$82	1.4 x	1.4 x	1.2 x
		Mean	**$2,012**	**1,958**	**$478**	**$460**	**$552**	**12.8 x**	**10.9 x**	**6.0 x**

Source: Bloomberg and Wall Street Research
Note: LTM = Latest Twelve Months
(1) Stock price as of January 31, 2015
(2) Enterprise Value equals Equity Value plus debt less cash

Capitalization Table

January 1, 2015	Shares Outstanding	WAEP
Outstanding common shares (PTBI)	20,683,248	-
Warrants (PTBIW, fully traded)	3,500,000	$5.00
Warrants (non-traded)	577,756	$46.50
Options	233,834	$23.60
Fully Diluted Total	**24,994,838**	

Recent events:

PTBI recently completed a ~$14 million financing and uplisting to NASDAQ

No long term debt, no convertible preferred stock

Investment Highlights

- ✓ ***Commercial stage biopharmaceutical company driving innovation in plasma proteins***
- ✓ ***Patented, disruptive fractionation process***
  - ~$21bn market, 11% CAGR
  - Alpha-1 Proteinase Inhibitor ("A1PI") shortage looming, poor Cohn yield
  - SDF Process increases yields and margins
  - A1PI, Immunoglobulin, Ultra-orphan protein targets
- ✓ ***Focus on A1PI***
- ✓ ***Polymer Hydrogel Technology***
- ✓ ***Business Development – Partnering / M&A***